Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company using artificial intelligence to develop cancer therapies, has announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter financial and operating results. The event, led by President and CEO Panna Sharma and members of the management team, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s RADR(R) and Open-Medicine AI platforms.
This announcement comes at a pivotal time for the company as it seeks to leverage its proprietary AI capabilities to accelerate drug development and create new revenue streams. The webcast will offer investors a comprehensive look at Lantern’s progress, particularly in its clinical pipeline, which includes LP-184, LP-284, and LP-300. LP-184, an acylfulvene, is being developed for various solid tumors and, through Lantern's wholly owned subsidiary Starlight Therapeutics, for pediatric central nervous system cancers. LP-284 targets hematologic and solid tumors, while LP-300 is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment.
The company's strategic focus on AI is further underscored by the commercial availability of withZeta.ai, a multi-agentic AI co-scientist platform now offered as a subscription-based research tool for the global biomedical and drug development community. This move represents a significant step toward diversifying Lantern’s business model beyond traditional pharmaceutical development. The platform, along with the RADR(R) platform, is central to the company's mission to transform how cancer therapies are discovered and brought to patients.
Lantern's operations are supported by an AI Center of Excellence in Bengaluru, India, and its headquarters in Dallas, Texas. The company's commitment to integrating AI across its research and development efforts could position it as a leader in the emerging field of AI-driven oncology. However, the financial sustainability of such initiatives remains a question, as the company continues to invest heavily in research and development while generating limited revenue from its AI platform thus far.
The upcoming webcast will likely provide clarity on the adoption of withZeta.ai and its contribution to the company's bottom line. Additionally, investors will be keen to hear about the progress of Lantern's clinical trials, particularly the HARMONIC trial, which could yield significant data in the coming quarters. The company's ability to execute on its milestones and manage its cash runway will be crucial in determining its long-term viability.
For a full replay of the webcast, interested parties can visit the investor relations section of Lantern Pharma’s website. The company also maintains a newsroom at https://ibn.fm/LTRN for updates. As Lantern Pharma continues to blend AI innovation with clinical development, its progress will be closely watched by investors and the broader biotech community, making this webcast a key event for stakeholders.
